Effects of exenatide lar in type 2 diabetes mellitus and obesity

• Published in: Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral Vol. 31; no. 1; pp. 292 - 298
• Main Authors: Sierra Poyatos, Roberto, Riobó Serván, Pilar, Vázquez Martínez, Clotilde
• Format: Journal Article
• Language: Spanish
• Published: Spain 24.10.2014
• Subjects: Aged; Blood Glucose - analysis; Body Mass Index; Delayed-Action Preparations; Diabetes Mellitus, Type 2 - drug therapy; Female; Glycated Hemoglobin A - analysis; Humans; Hypoglycemic Agents - therapeutic use; Lipids - blood; Longitudinal Studies; Male; Middle Aged; Obesity - drug therapy; Peptides - therapeutic use; Retrospective Studies; Venoms - therapeutic use
• ISSN: 1699-5198
• DOI: 10.3305/nh.2015.31.1.8283

GLP-1 analogs have been shown to be an effective treatment of type 2 diabetes mellitus (DM-2) and obesity. Evaluate the efficacy of exenatide LAR on weight loss, glycemic control, blood pressure (BP) and lipid profile, in DM-2 and obesity. Retrospective study of patients treated with exenatide LAR for 6 months. Demographic data (age, gender), anthropometric, fasting glucose, glycated hemoglobin (HbA1c), blood pressure and lipid profile were collected at baseline and at 6 months after treatment. We performed a logistic regression analysis to assess possible predictors of efficacy. 30 patients (17 male, mean age: 61.7 ± 9.5 years old) with DM-2 of 9.7 ± 6.2 years of evolution. HbA1c was reduced by 1.3% (95%CI 1.04-1.57; p <0.001), weight by 2.8 kg (95%CI 1.67-3.96, p <0.001) and BMI by 1.9 kg/m2 (95%CI 1,08-2,93; p <0,001). Total cholesterol decreased by 26.9 mg/dl (95%CI 9.23-38.8, p = 0.003), LDL cholesterol by 21.2 mg/dl (95% CI 7.56-34.9, p = 0.02) and triglycerides by 53.9 mg/dl (95%CI 46.4-77.1 mg/dl, p = 0.004). No statistically significant changes in blood pressure and HDL cholesterol were observed. 53.3% of patients got an HbA1c <7%, 66.6% lost weight, and 43.3% simultaneously achieved both of them. Neither of the studied variables was confirmed as a predictor of treatment response. Regarding side effects, 53.3% reported gastrointestinal discomfort (nausea) and 26.6% reported subcutaneous nodules of spontaneous resolution. Treatment with exenatide LA, in obesity and DM-2, has shown beneficial effect on lipid weight, BMI, glycemic control and lipid profile, despite the long duration of diabetes in our patients.